Postmenopausal Osteoporosis clinical trials

Explore recruiting postmenopausal osteoporosis clinical trials.

Recruiting postmenopausal osteoporosis studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Postmenopausal Osteoporosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis

Czechia, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis

France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mineral Density

Bulgaria, Estonia, Poland, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

The effect of denosumab on muscle and strength and insulin sensitivity

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.

Italy

Therapeutic use (Phase IV) EU CTIS Study details

Postmenopausal Osteoporosis trials by city

Postmenopausal Osteoporosis clinical trials

Recruiting postmenopausal osteoporosis studies right now

Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

Combined Anabolic Therapy

Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis

Prunes Preventing Bone Loss in Perimenopause

A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens

A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis

StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures

Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women

Also recruiting in Europe

A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis

Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mineral Density

The effect of denosumab on muscle and strength and insulin sensitivity

Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.

Postmenopausal Osteoporosis trials by city

Other conditions